TY - JOUR AU - Jemal, A. AU - Siegel, R. AU - Xu, J. AU - Ward, E. PY - 2010 DA - 2010// TI - Cancer statistics, 2010 JO - CA Cancer J Clin VL - 60 UR - https://doi.org/10.3322/caac.20073 DO - 10.3322/caac.20073 ID - Jemal2010 ER - TY - JOUR AU - Zhu, A. X. PY - 2006 DA - 2006// TI - Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? JO - Oncologist VL - 11 UR - https://doi.org/10.1634/theoncologist.11-7-790 DO - 10.1634/theoncologist.11-7-790 ID - Zhu2006 ER - TY - JOUR AU - Llovet, J. M. AU - Ricci, S. AU - Mazzaferro, V. AU - Hilgard, P. AU - Gane, E. AU - Blanc, J. F. PY - 2008 DA - 2008// TI - Sorafenib in advanced hepatocellular carcinoma JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708857 DO - 10.1056/NEJMoa0708857 ID - Llovet2008 ER - TY - JOUR AU - Cheng, A. L. AU - Kang, Y. K. AU - Chen, Z. AU - Tsao, C. J. AU - Qin, S. AU - Kim, J. S. PY - 2009 DA - 2009// TI - Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial JO - Lancet Oncol VL - 10 UR - https://doi.org/10.1016/S1470-2045(08)70285-7 DO - 10.1016/S1470-2045(08)70285-7 ID - Cheng2009 ER - TY - JOUR AU - Deng, G. H. AU - Liu, J. AU - Zhang, J. AU - Wang, Y. AU - Peng, X. C. AU - Wei, Y. Q. PY - 2014 DA - 2014// TI - Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model JO - J Exp Clin Cancer Res VL - 33 UR - https://doi.org/10.1186/1756-9966-33-21 DO - 10.1186/1756-9966-33-21 ID - Deng2014 ER - TY - JOUR AU - Cooper, C. S. AU - Park, M. AU - Blair, D. G. AU - Tainsky, M. A. AU - Huebner, K. AU - Croce, C. M. PY - 1984 DA - 1984// TI - Molecular cloning of a new transforming gene from a chemically transformed human cell line JO - Nature VL - 311 UR - https://doi.org/10.1038/311029a0 DO - 10.1038/311029a0 ID - Cooper1984 ER - TY - JOUR AU - Birchmeier, C. AU - Birchmeier, W. AU - Gherardi, E. AU - Vande Woude, G. F. PY - 2003 DA - 2003// TI - Met, metastasis, motility and more JO - Nat Rev Mol Cell Biol VL - 4 UR - https://doi.org/10.1038/nrm1261 DO - 10.1038/nrm1261 ID - Birchmeier2003 ER - TY - JOUR AU - Ma, P. C. AU - Maulik, G. AU - Christensen, J. AU - Salgia, R. PY - 2003 DA - 2003// TI - c-Met: structure, functions and potential for therapeutic inhibition JO - Cancer Metastasis Rev VL - 22 UR - https://doi.org/10.1023/A:1023768811842 DO - 10.1023/A:1023768811842 ID - Ma2003 ER - TY - JOUR AU - Boccaccio, C. AU - Comoglio, P. M. PY - 2006 DA - 2006// TI - Invasive growth: a MET-driven genetic programme for cancer and stem cells JO - Nat Rev Cancer VL - 6 UR - https://doi.org/10.1038/nrc1912 DO - 10.1038/nrc1912 ID - Boccaccio2006 ER - TY - JOUR AU - Gao, J. J. AU - Inagaki, Y. AU - Xue, X. AU - Qu, X. J. AU - Tang, W. PY - 2011 DA - 2011// TI - c-Met: A potential therapeutic target for hepatocellular carcinoma JO - Drug Discov Ther VL - 5 UR - https://doi.org/10.5582/ddt.2011.v5.1.2 DO - 10.5582/ddt.2011.v5.1.2 ID - Gao2011 ER - TY - JOUR AU - Chu, J. S. AU - Ge, F. J. AU - Zhang, B. AU - Wang, Y. AU - Silvestris, N. AU - Liu, L. J. PY - 2013 DA - 2013// TI - Expression and prognostic value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma JO - J Exp Clin Cancer Res VL - 32 UR - https://doi.org/10.1186/1756-9966-32-16 DO - 10.1186/1756-9966-32-16 ID - Chu2013 ER - TY - JOUR AU - Xiang, Q. AU - Chen, W. AU - Ren, M. AU - Wang, J. AU - Zhang, H. AU - Deng, D. Y. PY - 2014 DA - 2014// TI - Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2620 DO - 10.1158/1078-0432.CCR-13-2620 ID - Xiang2014 ER - TY - JOUR AU - You, H. AU - Ding, W. AU - Dang, H. AU - Jiang, Y. AU - Rountree, C. B. PY - 2011 DA - 2011// TI - c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma JO - Hepatology VL - 54 UR - https://doi.org/10.1002/hep.24450 DO - 10.1002/hep.24450 ID - You2011 ER - TY - JOUR AU - Shojaei, F. AU - Lee, J. H. AU - Simmons, B. H. AU - Wong, A. AU - Esparza, C. O. AU - Plumlee, P. A. PY - 2010 DA - 2010// TI - HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-10-0489 DO - 10.1158/0008-5472.CAN-10-0489 ID - Shojaei2010 ER - TY - JOUR AU - Tomaso, E. AU - Snuderl, M. AU - Kamoun, W. S. AU - Duda, D. G. AU - Auluck, P. K. AU - Fazlollahi, L. PY - 2011 DA - 2011// TI - Glioblastoma recurrence after cediranib therapy in patients: lack of “rebound” revascularization as mode of escape JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-10-2602 DO - 10.1158/0008-5472.CAN-10-2602 ID - Tomaso2011 ER - TY - JOUR AU - Paez-Ribes, M. AU - Allen, E. AU - Hudock, J. AU - Takeda, T. AU - Okuyama, H. AU - Vinals, F. PY - 2009 DA - 2009// TI - Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis JO - Cancer Cell VL - 15 UR - https://doi.org/10.1016/j.ccr.2009.01.027 DO - 10.1016/j.ccr.2009.01.027 ID - Paez-Ribes2009 ER - TY - JOUR AU - Xu, Y. AU - Li, Q. AU - Li, X. Y. AU - Yang, Q. Y. AU - Xu, W. W. AU - Liu, G. L. PY - 2012 DA - 2012// TI - Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis JO - J Exp Clin Cancer Res VL - 31 UR - https://doi.org/10.1186/1756-9966-31-16 DO - 10.1186/1756-9966-31-16 ID - Xu2012 ER - TY - JOUR AU - Verslype, C. AU - Cohn, A. L. AU - Kelley, R. K. AU - Yang, T. -. S. AU - Su, W. -. C. AU - Ramies, D. A. PY - 2012 DA - 2012// TI - Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT) JO - J Clin Oncol VL - 30 ID - Verslype2012 ER - TY - JOUR AU - Lee, R. J. AU - Saylor, P. J. AU - Michaelson, M. D. AU - Rothenberg, S. M. AU - Smas, M. E. AU - Miyamoto, D. T. PY - 2013 DA - 2013// TI - A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0319 DO - 10.1158/1078-0432.CCR-13-0319 ID - Lee2013 ER - TY - JOUR AU - Elisei, R. AU - Schlumberger, M. J. AU - Muller, S. P. AU - Schoffski, P. AU - Brose, M. S. AU - Shah, M. H. PY - 2013 DA - 2013// TI - Cabozantinib in progressive medullary thyroid cancer JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.48.4659 DO - 10.1200/JCO.2012.48.4659 ID - Elisei2013 ER - TY - JOUR AU - Munshi, N. AU - Jeay, S. AU - Li, Y. AU - Chen, C. R. AU - France, D. S. AU - Ashwell, M. A. PY - 2010 DA - 2010// TI - ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity JO - Mol Cancer Ther VL - 9 UR - https://doi.org/10.1158/1535-7163.MCT-09-1173 DO - 10.1158/1535-7163.MCT-09-1173 ID - Munshi2010 ER - TY - JOUR AU - Sharma, N. AU - Adjei, A. A. PY - 2011 DA - 2011// TI - In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs JO - Ther Adv Med Oncol VL - 3 UR - https://doi.org/10.1177/1758834011423403 DO - 10.1177/1758834011423403 ID - Sharma2011 ER - TY - JOUR AU - Santoro, A. AU - Rimassa, L. AU - Borbath, I. AU - Daniele, B. AU - Salvagni, S. AU - Laethem, J. L. PY - 2013 DA - 2013// TI - Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(12)70490-4 DO - 10.1016/S1470-2045(12)70490-4 ID - Santoro2013 ER - TY - JOUR AU - Katayama, R. AU - Aoyama, A. AU - Yamori, T. AU - Qi, J. AU - Oh-hara, T. AU - Song, Y. PY - 2013 DA - 2013// TI - Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-3256 DO - 10.1158/0008-5472.CAN-12-3256 ID - Katayama2013 ER - TY - JOUR AU - Basilico, C. AU - Pennacchietti, S. AU - Vigna, E. AU - Chiriaco, C. AU - Arena, S. AU - Bardelli, A. PY - 2013 DA - 2013// TI - Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-3459 DO - 10.1158/1078-0432.CCR-12-3459 ID - Basilico2013 ER - TY - JOUR AU - Remsing Rix, L. L. AU - Kuenzi, B. M. AU - Luo, Y. AU - Remily-Wood, E. AU - Kinose, F. AU - Wright, G. PY - 2014 DA - 2014// TI - GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells JO - ACS Chem Biol VL - 9 UR - https://doi.org/10.1021/cb400660a DO - 10.1021/cb400660a ID - Remsing Rix2014 ER - TY - JOUR AU - Etnyre, D. AU - Stone, A. L. AU - Fong, J. T. AU - Jacobs, R. J. AU - Uppada, S. B. AU - Botting, G. M. PY - 2014 DA - 2014// TI - Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy JO - Cancer Biol Ther VL - 15 UR - https://doi.org/10.4161/cbt.29451 DO - 10.4161/cbt.29451 ID - Etnyre2014 ER - TY - JOUR AU - Zhang, D. M. AU - Shu, C. AU - Chen, J. J. AU - Sodani, K. AU - Wang, J. AU - Bhatnagar, J. PY - 2012 DA - 2012// TI - BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo JO - Mol Pharm VL - 9 UR - https://doi.org/10.1021/mp300249s DO - 10.1021/mp300249s ID - Zhang2012 ER - TY - JOUR AU - Xiang, Q. F. AU - Zhang, D. M. AU - Wang, J. N. AU - Zhang, H. W. AU - Zheng, Z. Y. AU - Yu, D. C. PY - 2015 DA - 2015// TI - Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein JO - Liver Int VL - 35 UR - https://doi.org/10.1111/liv.12524 DO - 10.1111/liv.12524 ID - Xiang2015 ER - TY - JOUR AU - Jordan, M. A. AU - Thrower, D. AU - Wilson, L. PY - 1991 DA - 1991// TI - Mechanism of inhibition of cell proliferation by Vinca alkaloids JO - Cancer Res VL - 51 ID - Jordan1991 ER - TY - JOUR AU - Zhang, Y. AU - Guessous, F. AU - Kofman, A. AU - Schiff, D. AU - Abounader, R. PY - 2010 DA - 2010// TI - XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC JO - IDrugs VL - 13 ID - Zhang2010 ER - TY - JOUR AU - Niero, E. L. AU - Rocha-Sales, B. AU - Lauand, C. AU - Cortez, B. A. AU - Souza, M. M. AU - Rezende-Teixeira, P. PY - 2014 DA - 2014// TI - The multiple facets of drug resistance: one history, different approaches JO - J Exp Clin Cancer Res VL - 33 UR - https://doi.org/10.1186/1756-9966-33-37 DO - 10.1186/1756-9966-33-37 ID - Niero2014 ER - TY - JOUR AU - Ng, I. O. AU - Liu, C. L. AU - Fan, S. T. AU - Ng, M. PY - 2000 DA - 2000// TI - Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response JO - Am J Clin Pathol VL - 113 UR - https://doi.org/10.1309/AC1M-4TY4-U0TN-EN7T DO - 10.1309/AC1M-4TY4-U0TN-EN7T ID - Ng2000 ER - TY - JOUR AU - Zhang, S. Z. AU - Pan, F. Y. AU - Xu, J. F. AU - Yuan, J. AU - Guo, S. Y. AU - Dai, G. PY - 2005 DA - 2005// TI - Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo JO - Mol Cancer Ther VL - 4 UR - https://doi.org/10.1158/1535-7163.MCT-05-0106 DO - 10.1158/1535-7163.MCT-05-0106 ID - Zhang2005 ER - TY - JOUR AU - Boutros, R. AU - Lobjois, V. AU - Ducommun, B. PY - 2007 DA - 2007// TI - CDC25 phosphatases in cancer cells: key players? Good targets? JO - Nat Rev Cancer VL - 7 UR - https://doi.org/10.1038/nrc2169 DO - 10.1038/nrc2169 ID - Boutros2007 ER - TY - JOUR AU - Abbas, T. AU - Dutta, A. PY - 2009 DA - 2009// TI - p21 in cancer: intricate networks and multiple activities JO - Nat Rev Cancer VL - 9 UR - https://doi.org/10.1038/nrc2657 DO - 10.1038/nrc2657 ID - Abbas2009 ER - TY - JOUR AU - Cai, S. AU - Ye, Z. AU - Wang, X. AU - Pan, Y. AU - Weng, Y. AU - Lao, S. PY - 2015 DA - 2015// TI - Overexpression of P21-activated kinase 4 is associated with poor prognosis in non-small cell lung cancer and promotes migration and invasion JO - J Exp Clin Cancer Res VL - 34 UR - https://doi.org/10.1186/s13046-015-0165-2 DO - 10.1186/s13046-015-0165-2 ID - Cai2015 ER - TY - JOUR AU - Elmore, S. PY - 2007 DA - 2007// TI - Apoptosis: a review of programmed cell death JO - Toxicol Pathol VL - 35 UR - https://doi.org/10.1080/01926230701320337 DO - 10.1080/01926230701320337 ID - Elmore2007 ER - TY - JOUR AU - Yang, T. AU - Shi, R. AU - Chang, L. AU - Tang, K. AU - Chen, K. AU - Yu, G. PY - 2015 DA - 2015// TI - Huachansu suppresses human bladder cancer cell growth through the Fas/Fasl and TNF- alpha/TNFR1 pathway in vitro and in vivo JO - J Exp Clin Cancer Res VL - 34 UR - https://doi.org/10.1186/s13046-015-0134-9 DO - 10.1186/s13046-015-0134-9 ID - Yang2015 ER - TY - JOUR AU - Zhang, Z. AU - Wang, M. AU - Zhou, L. AU - Feng, X. AU - Cheng, J. AU - Yu, Y. PY - 2015 DA - 2015// TI - Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer JO - J Exp Clin Cancer Res VL - 34 UR - https://doi.org/10.1186/s13046-015-0166-1 DO - 10.1186/s13046-015-0166-1 ID - Zhang2015 ER - TY - JOUR AU - Dejean, L. M. AU - Ryu, S. Y. AU - Martinez-Caballero, S. AU - Teijido, O. AU - Peixoto, P. M. AU - Kinnally, K. W. PY - 2010 DA - 2010// TI - MAC and Bcl-2 family proteins conspire in a deadly plot JO - Biochim Biophys Acta VL - 1797 UR - https://doi.org/10.1016/j.bbabio.2010.01.007 DO - 10.1016/j.bbabio.2010.01.007 ID - Dejean2010 ER - TY - JOUR AU - Dejean, L. M. AU - Martinez-Caballero, S. AU - Manon, S. AU - Kinnally, K. W. PY - 2006 DA - 2006// TI - Regulation of the mitochondrial apoptosis-induced channel, MAC, by BCL-2 family proteins JO - Biochim Biophys Acta VL - 1762 UR - https://doi.org/10.1016/j.bbadis.2005.07.002 DO - 10.1016/j.bbadis.2005.07.002 ID - Dejean2006 ER -